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Abstract
Background: Ticagrelor is a reversible and direct-acting oral antagonist of the adenosine diphosphate receptor
P2Y12. Possible adenosine-mediated effects of ticagrelor on inflammation are complex and incompletely understood.
To our knowledge, ticagrelor-induced systemic inflammatory response syndrome (SIRS) has not yet been described.
Case presentation: We report the case of an 84 years old patient presenting with SIRS subsequent to initiation of
ticagrelor after implantation of two drug eluting stents. A broad diagnostic work-up for alternative causes and
therapeutic measures were unrevealing. Discontinuation of the agent was followed by rapid improvement in clinical
and laboratory signs of SIRS.
Conclusions: After exclusion of other causes, ticagrelor needs to be considered as a possible causative agent for SIRS.
Due to the widespread use of ticagrelor, clinicians should be aware of this possible adverse drug reaction.
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Background
Ticagrelor, a reversible and direct-acting oral antagonist of
the adenosine diphosphate receptor P2Y12, significantly
reduced death as compared to clopidogrel in patients with
acute coronary syndrome [1]. This led to widespread use
of the agent and implementation in current guidelines [2].
Possible adenosine-mediated effects of ticagrelor on in-
flammation are complex and incompletely understood [3].
Due to the lower incidence of sepsis and pulmonary ad-
verse events as well as lower mortality in patients taking
ticagrelor versus clopidogrel, such effects were previously
considered to be beneficial. To our knowledge, ticagrelor-
induced systemic inflammatory response syndrome (SIRS)
has not yet been described.
Case presentation
We present the case of an 84 years old male presenting
with dyspnea (NYHA III) and fatigue, hypotension (88/
50 mmHg), tachycardia (97 bpm), and fever (38.4 °Celsius)
to our emergency department fulfilling 2 of 4 criteria for
SIRS [4]. Clinical examination was significant for discrete
bibasal pulmonary rales and a 2/6 systolic murmur, in
agreement with a preexisting, moderate mitral valve
insufficiency. Initial laboratory findings showed substan-
tially elevated C-reactive protein (CRP) (84 mg/l) and
serum creatinine (159 μmol/l).
Recent medical history was significant for ST-elevation
myocardial infarction (STEMI) 15 days prior to the
current presentation with successful percutaneous coron-
ary intervention and implantation of two drug eluting
stents in the proximal right coronary artery. Other rele-
vant comorbidities included pre-existing coronary artery
disease, arterial hypertension and hypercholesterolemia.
His current medication included aspirin, ticagrelor, nebi-
volol, olmesartan, rosuvastatin and pantoprazol, with tica-
grelor initiated 15 days ago. He had no history of allergies.
Empirical antibiotic treatment with ceftriaxone was
initiated in the emergency department due to suspected
severe sepsis after blood and urine culture sampling.
Extensive infectious disease work-up including blood
cultures, a respiratory panel for the comprehensive de-
tection of respiratory disease-causing viruses and bac-
teria, HIV testing, and imaging studies (CT-scan of the
chest, abdominal ultrasound, transthoracic and transoe-
sophageal echocardiography) did not reveal an infectious
cause of SIRS.
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Symptoms (dyspnea and fatigue), signs (fever), and la-
boratory signs (CRP) of SIRS persisted despite 6 days of
intravenous antibiotic treatment (Fig. 1). Further, Dressler-
Syndrome was considered as a differential diagnosis. How-
ever, lack of a pericardial rub, leukocytosis, pericardial
effusion, or clinical and laboratory response to preemptive
treatment with ibuprofen rendered it very unlikely.
After broad, unrevealing diagnostic work-up ticagrelor
was suspected as the causative agent of persistent SIRS
due to recent initiation and no other change in drug
treatment. Accordingly, ticagrelor was discontinued at
day seven and replaced by clopidogrel. No other drug
was changed during the hospital stay. This was followed
by a rapid improvement in symptoms as well as clinical
and laboratory signs of SIRS. In clinical follow-up
2 weeks and 1 year after discharge the patient remained
asymptomatic and well.
Discussion
To our knowledge this is the first report describing tica-
grelor induced SIRS. The close temporal association be-
tween the initiation and discontinuation of ticagrelor
with the onset and resolution of SIRS, as well as the lack
of evidence for an alternative cause despite extensive
diagnostic and therapeutic measures justify considering
a causal relationship as possible. Two unlikely differen-
tial diagnoses remain. First, the patient could have suf-
fered from sepsis due to viral infection which escaped
detection despite the broad diagnostic work-up and by
chance resolved exactly at the time of discontinuation of
ticagrelor. Second, the patient could have suffered from
a self-limiting non-infectious inflammatory disease with-
out any additional rheumatologic symptoms and/or
signs, which by chance started soon after the initiation
of ticagrelor and also by chance resolved exactly at the
time of discontinuation of ticagrelor.
A recent study showed discontinuation of ticagrelor in
17% of treated patients. Conventional side effects of tica-
grelor included dyspnea, bleeding, dizziness, rash, itch-
ing and gastrointestinal adverse reactions. However the
most frequent cause of discontinuation was the need for
oral anticoagulation therapy [5]. Additionally frequent
comorbidities in patients with ischemic heart disease like
chronic obstructive pulmonary disease may influence
discontinuation rates of ticagrelor. This is mainly due to
known side effects including dyspnea and bleeding [6].
However evidence is missing to suggest a different use
of ticagrelor in this patient population [7].
Interactions between platelet P2Y12 inhibitors and the
immune system result in both favorable, including re-
duced incidence of sepsis and pulmonary adverse events,
and adverse, including elevation of CRP and dyspnea,
effects [1, 3]. Underlying mechanisms are not fully
understood. Potential mechanisms are inhibition of
leukocyte-platelet interactions with alterations in more
downstream inflammatory processes, the inhibition of
P2Y12 receptors on other cells, including dendritic and
vascular smooth muscle cells, and an increase in
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Fig. 1 C-reactive protein levels in relation to ticagrelor treatment
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extracellular adenosine [3]. Adenosine acts at low concen-
trations pro-inflammatory via activation of leukocyte A1
receptors. Thereby chemotaxis of neutrophils and phago-
cytosis of neutrophils and macrophages are facilitated.
However, at higher concentrations mostly leukocyte A2 re-
ceptors are activated with subsequent decreased release of
pro-inflammatory cytokines. Ticagrelor-induced changes
in adenosine levels may therefore induce an imbalance in
this complex system [3].
It is therefore important to consider ticagrelor as a
causative agent in a patient presenting with SIRS soon
after the initiation of ticagrelor. Further research is ur-
gently needed to better elucidate the interactions be-
tween ticagrelor and the immune system considering the
widespread use of the drug.
Conclusions
Ticagrelor needs to be considered as a possible causative
agent in patients presenting with SIRS whenever the
diagnostic work-up for infectious causes is unrevealing.
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